BRD9 inhibition overcomes oncolytic virus therapy resistance in glioblastoma
We identified the ncBAF complex as a crucial element in oncolytic virus resistance. Genetic or pharmacological targeting of the ncBAF-specific subunit BRD9 significantly enhanced the potency of oncolytic Herpes Simplex Virus-1 (oHSV1) against glioblastoma.